San Diego Biotechnology Network’s Post

SDBN Trending News: Sapient Partners with Alamar Biosciences to Extend Targeted Proteomics Services Using NULISA™ Assays for Cytokines, Chemokines, and Inflammatory Mediators https://lnkd.in/gkeatew4 SAN DIEGO–(BUSINESS WIRE)– #chemokineassays–Sapient, a leader in multi-omics discovery, has partnered with Alamar Biosciences, a pioneer in ultra-sensitive and highly multiplexed immunoassay technologies, to extend its targeted proteomics services to include high-sensitivity cytokine, chemokine, and [...]

if you are interested in targeted protein degradation (#TPD), check this preprint where the authors developed a high-throughput proteome-wide screening platform using label-free DIA-MS to identify novel neosubstrates. This opens new doors in Molecular glue drug discovery by revealing potent, selective degraders and expanding the CRBN-mediated neosubstrate landscape. #proteomics #drugdiscovery #biotech #cancerresearch https://lnkd.in/ey4epcMV

World’s Largest Proteome Study is leveraging Olink Technology. The UK Biobank Pharma Proteomics Project will analyse over 600,000 samples to map disease-associated protein levels and advance biomarker discovery. The study is a collaboration between UK Biobank and 14 leading biopharmaceutical companies. It comes as no surprise that Olink has been chosen for this monumental study, as Olink stands as the undisputed world leader in the affinity proteomics field. With over 19,000 researchers worldwide already using UK Biobank data, this initiative is poised to have a major impact. Massive proteomics studies such as the UK Biobank Pharma Proteomics Project are transforming our understanding of health and disease by revealing how proteins influence biological processes. These efforts are paving the way for earlier diagnoses, better treatments, and precision medicine — helping to improve lives and reduce the burden of disease worldwide. Explore how our Olink services can accelerate your research: www.bioxpedia.com #Proteomics #ClinicalResearch #PrecisionMedicine #LifeSciences #DrugDevelopment

NEWS RELEASE WRN degradation and efficacy test, alone with WRNi HRO-761 resistant cell line generation. Happy to share our WRN cell panel list with proteomics and RNAseq analysis for drug discovery program. Freel free to reach out more screening assays for WRN and DDR targets. #WRN #Degradation #ResistantCellLine #Screening #ICEBioscience #CellPanel #Proteomics #RNAseq

𝗗𝗶𝘀𝗰𝗼𝘃𝗲𝗿 𝗭𝗧 𝗦𝗰𝗮𝗻 𝗗𝗜𝗔 𝗳𝗼𝗿 𝗾𝘂𝗮𝗻𝘁𝗶𝘁𝗮𝘁𝗶𝘃𝗲 𝗽𝗿𝗼𝘁𝗲𝗼𝗺𝗶𝗰𝘀! ZT Scan DIA combines the depth of data independent acquisition (DIA) method with the precision of targeted approaches, delivering precise quantitative outcomes at up to ten times the speed of conventional DIA methods. Make crucial therapeutic pathway decisions with confidence. Discover how ZT Scan DIA bridges the gap between identification and translation, allowing you to better understand disease states and the efficacy of precision therapeutics. Visit our website to learn more about this innovative solution and stay ahead of the next (r)evolution in #DIA-based mass spectrometry 👉 https://sciex.li/3u76dc Learn more about this news in Technology Networks 👉 https://bit.ly/3Rn46CJ #DanaherNews #Proteomics #BiomarkerResearch #ZTScanDIA #QuantitativeAnalysis #MassSpec #ZenoRevolution

📌 We are excited to attend the LSX World Congress USA 2024 in Boston, USA, on September 11-12, 2024. Meet Nhakulan Dhamodharan and Shilpi Priyadarshini at the Congress to discuss how Syngene can help you accelerate your drug discovery programs.   To book a meeting with our experts, visit the link in the comments section.   Our capabilities include: ⦿ Antibody Discovery & Development ⦿ Extensive In-Vitro & In-Vivo Biological Assay Capability ⦿ Cell Line Development & Analysis ⦿ CAR-T Therapy Research ⦿ Therapeutic Clone Development & Manufacturing ⦿ Critical Reagent generation and assay development ⦿ Large-scale protein expression (Bacterial, Insect, Pichia and Mammalian) and more... #LSX2024 #DiscoveryServices #Syngene

Membrane proteins are essential for various cellular processes, including signal transduction and disease progression. Efficient and accurate screening is vital for the development of small-molecule therapeutics targeting membrane proteins. In recent years, affinity selection mass spectrometry (ASMS) has become a powerful tool for studying membrane protein-small molecule interactions and this technique has demonstrated significant potential in drug discovery and development. The ASMS platform at WuXi Biology is backed by a library of over 270,000 small molecules and offers customized screening services. In a recent article, we highlight the effectiveness of integrating ASMS with machine learning for GLUT1 membrane protein screening. Click 👇 this link to learn more: https://lnkd.in/gRiC__58 #Biotech #ASMS #MembraneProteins #AffinitySelection #GLUT1 #ML

A Comprehensive Review of Monoclonal Antibodies in Modern Medicine: Tracing the Evolution of a Revolutionary Therapeutic Approach Monoclonal antibodies (mAbs) have emerged as potent therapeutic agents, revolutionizing the landscape of modern medicine. This comprehensive review traces the evolution of mAbs from their inception to their current prominence, highlighting key milestones in their development and exploring their diverse therapeutic applications. Beginning with an overview of their molecular structure and mechanisms of action, we delve into the production and engineering of mAbs, including hybridoma technology and recombinant DNA techniques. https://lnkd.in/gtG3r7QH #aspenalert #biotech #bioprocess

🧬 𝐁𝐚𝐬𝐞 𝐄𝐝𝐢𝐭𝐢𝐧𝐠 𝐌𝐚𝐫𝐤𝐞𝐭 𝐒𝐞𝐭 𝐭𝐨 𝐄𝐱𝐩𝐥𝐨𝐝𝐞! 🚀 Download a PDF Brochure: https://lnkd.in/g5J_cHwi • Projected to reach $549M by 2028 • Impressive 15.2% CAGR from 2023-2028 • DNA base editing leading the charge • North America dominates the market Key drivers: • Growing interest in gene editing • Substantial funding for R&D • Shift towards precision medicine 𝐓𝐡𝐞 𝐜𝐨𝐦𝐩𝐚𝐧𝐢𝐞𝐬 𝐟𝐞𝐚𝐭𝐮𝐫𝐞𝐝 𝐢𝐧 𝐭𝐡𝐢𝐬 𝐫𝐞𝐩𝐨𝐫𝐭 𝐢𝐧𝐜𝐥𝐮𝐝𝐞: Danaher Corporation (US), Merck KGaA (Germany), Revvity (US), Maravai LifeSciences (US), GenScript (China), Beam Therapeutics (US), Intellia Therapeutics, Inc. (US), Cellectis (France), ElevateBio (US), Creative Biogene (US), Bio Palette Co., Ltd (Japan), Addgene (US), Synthego (US), Edigene, Inc. (China), Shape TX (US), Pairwise (US), ProQR Therapeutics (Netherlands), QI- Biodesign (China), KromaTiD, Inc. (US), and GenKOre. (South Korea) Other Companies that are Operating in this Market Globally: Beam Therapeutics Mammoth Biosciences Modalis Therapeutics EdiGene Inc. INOVIO Pharmaceuticals, Inc. Addgene VGXI Phase Genomics 3P Biopharmaceuticals Patheon Touchlight Lifera Fisher Clinical Services Akron Bio Biovian OXGENE Andelyn Biosciences Plasmidsaurus InvivoGen NorthX Biologics Genprex, Inc. BioCina Eurofins Genomics Americas      Eurogentec 4basebio ANEMOCYTE CATUG Matinas BioPharma Mediphage Bioceuticals #BaseEditing #BiotechTrends #GenomicInnovation

We announced our Full-Year 2024 results today with sales of CHF 6.6 billion, and CORE EBITDA of CHF 1.9 billion resulting in a robust a margin of 29.0%. CDMO sales were driven by low-teens underlying CER growth, supported by strong performance in the Mammalian, Bioconjugates, Small Molecules and Cell & Gene Technologies businesses. This positive momentum compensated for the 2023 loss of COVID-related mRNA business, lower market demand for capsules within the CHI division, and softness in the Bioscience business. Thank you to all our colleagues at Lonza who continue to deliver for our business, our shareholders, our customers and their patients. Read the full news release here: https://lnkd.in/ePmTE8jG #FinancialResults #CDMO #Lonza